# BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Source: https://onco.cc/trials/nct05393466/  
OnCo record `nct05393466` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in lung cancer, run by Xcovery Holdings, Inc., not yet recruiting.

## Summary

BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) is a phase 1/2, interventional study registered as NCT05393466 by Xcovery Holdings, Inc., with a registry enrolment figure of 30 participants, started 2026-07-01 and due to reach its primary completion in 2028-01-30. Interventions recorded: BPI-361175. Conditions listed: Non-small Cell Lung Carcinoma. Primary outcome: The percentage of patients with adverse events and serious adverse events graded per National Cancer Institute Common Terminology Criteria for Adverse Events and dose limiting toxicities for BPI 361175; Efficacy of BPI-361175. Lung eligibility wording from the registry: "Patients with histologically or cytologically confirmed diagnosis of inoperable locally advanced or recurrent/metastatic NSCLC with EGFR mutations". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05393466
- Phase: 1/2
- Setting: A Phase I/II, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
- Sponsor: Xcovery Holdings, Inc.
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT05393466: https://clinicaltrials.gov/study/NCT05393466

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Xcovery](https://onco.cc/companies/xcovery/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05393466.json